Shamburg News · 8-K filed Nov 17, 2026, 9:42 AM EST

Pacira BioSciences Completes Merger with Viatris; Shares Converted to $36.50 Cash

PCRX · Pacira BioSciences, Inc.

  • Acquisition
  • Material agreement
  • Financing
  • Delisting
  • Leadership change
  • Shareholder vote
  • Reg FD disclosure
  • Other event
  • Materiality: high

On November 17, 2026, Pacira BioSciences completed its merger with Viatris following a tender offer that was accepted at $36.50 per share in cash. The Company's common stock is to be delisted from Nasdaq, and the Company repaid $96,392.50 in full under its Credit Agreement and terminated it. Holders of the 2.125% Convertible Senior Notes due 2029 may convert at cash rates including Additional Shares through January 8, 2027, under a First Supplemental Indenture.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 1.02, 2.01, 2.04, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01, accession 0001140361-26-044354.

Written from the filing by Shamburg Markets. Figures are as reported by the company.